0001567619-23-006327.txt : 20230609 0001567619-23-006327.hdr.sgml : 20230609 20230608181947 ACCESSION NUMBER: 0001567619-23-006327 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230608 EFFECTIVENESS DATE: 20230609 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Renibus Therapeutics, Inc. CENTRAL INDEX KEY: 0001667699 IRS NUMBER: 810872431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-483766 FILM NUMBER: 231003311 BUSINESS ADDRESS: STREET 1: 181 GRAND AVE., SUITE 225 CITY: SOUTHLAKE STATE: TX ZIP: 76092 BUSINESS PHONE: 386-527-1071 MAIL ADDRESS: STREET 1: 181 GRAND AVE., SUITE 225 CITY: SOUTHLAKE STATE: TX ZIP: 76092 D 1 primary_doc.xml X0708 D LIVE 0001667699 Renibus Therapeutics, Inc. 181 Grand Ave., Suite 225 SOUTHLAKE TX TEXAS 76092 386-527-1071 DELAWARE None None Corporation true Carlos Guillem 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Director D. Jeffrey Keyser 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Director Executive Officer Henrik Rasmussen 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Director Bhupinder Singh 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Executive Officer Director Frank Stonebanks 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Executive Officer Director Jamie Donadio 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2023-05-25 false true false 0 73423067 63805500 9617567 The total offering amount and amount sold includes amounts from certain converting SAFEs, which may have been previously reported on Form D. The SAFEs converted into shares of Series B-1 Preferred Stock at the initial closing of the transaction. false 37 0 0 0 false Renibus Therapeutics, Inc. /s/ Frank Stonebanks Frank Stonebanks Co-Chief Executive Officer 2023-06-08